Baillière's Clinical Gastroenterology
Volume 8, Issue 2, June 1994, Pages 203-231
Salicylates for inflammatory bowel disease
References (160)
- et al.
Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid
Gastroenterology
(1990) - et al.
Sulphasalazine and salicylazosulphanilimide in ulcerative colitis
Lancet
(1962) - et al.
Long-term use of mesalamine enemas to induce remission in ulcerative colitis
Gastroenterology
(1990) - et al.
Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis
Lancet
(1992) - et al.
Role of platelet-activating factor in ulcerative colitis
- et al.
Sulphasalazine inhibits lyso PAF: acetyl-CoA acetyltransferase
Prostaglandins
(1992) - et al.
Bacterial chemotactic oligopeptides and the intestinal mucosal barrier
Gastroenterology
(1989) - et al.
Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study
- et al.
Placebo controlled trial of the treatment of ulcerative colitis with oral 4-aminosalicylic acid
Gastroenterology
(1992) - et al.
Neutrophil-mediated nitrosamine formation: role of nitric oxide in rats
Gastroenterology
(1992)
The effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis: a case control study
Gastroenterology
(1989)
European Co-operative Crohn's Disease Study (ECCDS): results of drug treatment
Gastroenterology
(1984)
Olsalazine sodium in the treatment of active ulcerative colitis in patients intolerant of sulfasalazine
Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis
Lancet
(1965)
Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis
Gastroenterology
(1988)
Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats
Journal of Pharmacological Science
(1979)
Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease
Gastroenterology
(1992)
Enhanced mucosal cytokine production in inflammatory bowel disease
Gastroenterology
(1992)
The effects of sulpha-salazine and its metabolites on prostaglandin production by human mononuclear cells
Biochemical Pharmacology
(1992)
Choosing an oral 5-aminosalicylic acid preparation for ulcerative colitis
Drug Therapy Bulletin
(1992)
The clinical effect of salazosulphapyridine (Salazopyrin) in Crohn's disease
Inhibition of cell-mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity
Gut
(1990)
An experiment to determine the active therapeutic moiety of sulphasalazine
Lancet
(1977)
Optimum dose of SASP for maintenance treatment in ulcerative colitis
Gut
(1980)
Post-operative treatment with corticosteroids and salazo-sulphapyridine (Salazopyrin) after radical resection for Crohn's disease
Scandinavian Journal of Gastroenterology
(1976)
Mesalazine (Pentasa) as prophylaxis in Crohn's disease
Lipid mediators and cytokines in inflammatory bowel disease
European Journal of Gastroenterology and Hepatology
(1990)
Nephrotoxic lesions from 5-aminosalicylic acid
British Medical Journal
(1972)
Optimum dosage of 5-ASA aminosalicylic acid as rectal enemas in patients with active ulcerative colitis
Gut
(1991)
5-Aminosalicylic acid in the prevention of Crohn's disease post-operative recurrence
Gastroenterology
(1992)
Aminoacid derivatives of 5-ASA as novel prodrugs for colon-specific drug delivery
Gastroenterology
(1993)
Interleukin-1 gene expression, synthesis and effect of specific IL-1 receptor blockade in rabbit immune complex colitis
Journal of Clinical Investigation
(1990)
IL-1 receptor antagonist (IL-IRA) blocks the pro-inflammatory activity of IL-1 produced in the colon during rabbit immune colitis
Gastroenterology
(1991)
Drug therapy of ulcerative colitis
British Journal of Clinical Pharmacology
(1992)
Salicylates used in inflammatory bowel disease and colchicine impair interferon-γ induced HLA-DR expression
Gut
(1992)
Inhibition of binding of interferon-γ to its receptor by salicylates used in inflammatory bowel disease
Gut
(1992)
Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis
Gut
(1990)
Maintenance of remission in ulcerative colitis with sulphasalazine or a high fibre diet: a clinical trial
British Medical Journal
(1978)
The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model
British Journal of Cancer
(1992)
Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid
British Medical Journal
(1982)
Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-aminosalicylic acid in normal subjects and patients with colitis
British Journal of Pharmacology
(1984)
Controlled trial of sulphasalazine in the treatment of ulcerative colitis
Gut
(1964)
A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin)
Gut
(1973)
Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects
Scandinavian Journal of Gastroenterology
(1988)
Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double blind trial
Gut
(1989)
Prevention of Crohn's disease recurrence after intestinal resection with Eudragit-L coated 5-aminosalicylic acid
Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis
Digestion
(1988)
Placebo-controlled trial of Claversal in the prevention of early endoscopic relapse after curative resection for Crohn's disease
Gastroenterology
(1992)
Relapse-prevention of ulcerative colitis: double-blind comparison of 1.5 g v 3 g oral mesalazine (Pentasa)
Gastroenterology
(1993)
Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid
Digestive Diseases and Sciences
(1991)
Cited by (11)
Progression and variability of TNBS colitis-associated inflammation in rats assessed by contrast-enhanced and T2-weighted MRI
2009, Inflammatory Bowel DiseasesLiver and gut mucosa acetylation of mesalazine in healthy volunteers
2000, International Journal of Clinical Pharmacology and Therapeutics
Copyright © 1994 Published by Elsevier Ltd.